Ideaya priced its shares below their range to raise $50m, providing exits for Alphabet, WuXi AppTec, Celgene, Roche and Novartis.

Ideaya Biosciences, a US-based precision medicine developer backed by corporates Alphabet, Celgene, Novartis, Roche and WuXi AppTec, raised $50m on Friday in an initial public offering on the Nasdaq Global Select Market.

The company issued 5 million shares priced at $10.00 each, representing an offering downsized from a range of $13 to $15. Its shares had risen to $11.25 by the close on Friday, giving it a market cap of nearly $163m.

Founded in 2015, Ideaya is developing small molecule…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn